AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate
This announcement contains inside information 27 July 2020 07:00 BST AstraZeneca and Daiichi Sankyo enter collaboration todevelop and commercialise new antibody drug conjugate Potential new medicine DS-1062 could redefine treatmentstandards in lung, breast and multiple other cancers AstraZeneca has entered into a new global development and commercialisation agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for DS-1062, Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) and potential new medicine for